Last reviewed · How we verify
GSK573719/GW642444 125/25
GSK573719/GW642444 125/25 is a LAMA/LABA combination Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Chronic obstructive pulmonary disease (COPD) maintenance therapy. Also known as: GSK573719/vilanterol trifenatate.
GSK573719/GW642444 is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-2 agonist (LABA) that relaxes airway smooth muscle and reduces mucus secretion to improve airflow in chronic obstructive pulmonary disease.
GSK573719/GW642444 is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta-2 agonist (LABA) that relaxes airway smooth muscle and reduces mucus secretion to improve airflow in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | GSK573719/GW642444 125/25 |
|---|---|
| Also known as | GSK573719/vilanterol trifenatate |
| Sponsor | GlaxoSmithKline |
| Drug class | LAMA/LABA combination |
| Target | Muscarinic M3 receptor / Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
GSK573719 (umeclidinium) is a LAMA that blocks muscarinic M3 receptors on airway smooth muscle, preventing bronchoconstriction. GW642444 (vilanterol) is a LABA that activates beta-2 adrenergic receptors, causing bronchodilation. Together, these complementary mechanisms provide sustained airway relaxation and improved lung function in COPD patients.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nervousness
Key clinical trials
- A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE3)
- An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B (PHASE3)
- 24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease (PHASE3)
- An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A (PHASE3)
- A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects (PHASE1)
- QTc Study GSK573719+GW642444 (PHASE1)
- Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses (PHASE1)
- 24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK573719/GW642444 125/25 CI brief — competitive landscape report
- GSK573719/GW642444 125/25 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GSK573719/GW642444 125/25
What is GSK573719/GW642444 125/25?
How does GSK573719/GW642444 125/25 work?
What is GSK573719/GW642444 125/25 used for?
Who makes GSK573719/GW642444 125/25?
Is GSK573719/GW642444 125/25 also known as anything else?
What drug class is GSK573719/GW642444 125/25 in?
What development phase is GSK573719/GW642444 125/25 in?
What are the side effects of GSK573719/GW642444 125/25?
What does GSK573719/GW642444 125/25 target?
Related
- Drug class: All LAMA/LABA combination drugs
- Target: All drugs targeting Muscarinic M3 receptor / Beta-2 adrenergic receptor
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Respiratory
- Indication: Drugs for Chronic obstructive pulmonary disease (COPD) maintenance therapy
- Also known as: GSK573719/vilanterol trifenatate
- Compare: GSK573719/GW642444 125/25 vs similar drugs
- Pricing: GSK573719/GW642444 125/25 cost, discount & access